Cerapedics' spinal bone graft earns approval for ACDF

Biologics

Cerapedics earned FDA approval to expand the use of its spinal fusion biologic, i-Factor P-15, according to a Sept. 24 news release.

Indications for the peptide enhanced bone graft now include single-level anterior cervical discectomy fusion with an allograft bone ring. It can also be used in conjunction with a PEEK titanium alloy or fusion device that has been cleared by the FDA for cervical spine use.

The i-Factor bone graft has been used in the U.S. since 2015, Cerapedic CEO Valeska Schroeder said in the release. It is reportedly the only product of its kind that used a P-15 osteogenic cell binding peptide, and studies show it is as safe as a local autograft in single-level ACDF.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy.
 

Articles We Think You'll Like

 

Thank you so much for your interest in our content. Please register to access this complimentary archived content. By registering, you will receive our newsletter which can be opted out of at any time.

 

 

Already Registered? Click here to confirm.